Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ERAS

Erasca Inc

Dec 19 • 04:00PM ET

3.45

-0.15 -4.17 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX ALNY RNA NTLA CRSP BEAM EDIT PFE AMGN

| Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT IWC DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	43.70%	Shs Outstand	283.71M	Perf Week	-4.17%
Market Cap	978.80M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.00%	Shs Float	159.73M	Perf Month	25.00%
Enterprise Value	738.69M	PEG	-	EPS next Q	-0.11	Inst Own	48.42%	Short Float	10.25%	Perf Quarter	93.82%
Income	-127.69M	P/S	-	EPS this Y	35.31%	Inst Trans	-1.49%	Short Ratio	8.17	Perf Half Y	148.20%
Sales	0.00M	P/B	2.81	EPS next Y	-5.06%	ROA	-26.90%	Short Interest	16.37M	Perf YTD	37.45%
Book/sh	1.23	P/C	3.39	EPS next 5Y	11.89%	ROE	-32.00%	52W High	3.80 -9.21%	Perf Year	31.18%
Cash/sh	1.02	P/FCF	-	EPS past 3/5Y	12.46% -46.86%	ROIC	-32.63%	52W Low	1.01 241.58%	Perf 3Y	-28.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.55% 7.65%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	45.66%	Oper. Margin	-	ATR (14)	0.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.46	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	10.45	EPS Q/Q	2.35%	SMA20	5.60%	Beta	1.14	Target Price	4.89
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	24.23%	Rel Volume	4.27	Prev Close	3.60
Employees	103	LT Debt/Eq	0.12	Earnings	Nov 12 AMC	SMA200	88.90%	Avg Volume	2.00M	Price	3.45
IPO	Jul 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.28% -	Trades		Volume	8,556,954	Change	-4.17%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	Stifel	Buy	$4
Sep-03-25	Downgrade	BofA Securities	Buy → Underperform
Aug-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$2
Mar-26-25	Initiated	Raymond James	Outperform	$5
Nov-18-24	Initiated	Jefferies	Buy	$6
Mar-11-24	Initiated	CapitalOne	Overweight	$8
Jan-05-24	Downgrade	BofA Securities	Buy → Neutral	$11 → $6
Oct-11-23	Initiated	H.C. Wainwright	Buy	$10
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Show Previous Ratings

Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Nov-29-25 01:26AM	Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results (Insider Monkey)
Nov-25-25 09:08AM	Erasca to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +6.23%
Nov-12-25 04:01PM	Erasca Reports Third Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +12.29%
Nov-06-25 08:00AM	Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 (GlobeNewswire)
08:00AM	Loading…
Nov-04-25 08:00AM	Erasca to Present at Upcoming Conferences in November (GlobeNewswire)
Oct-27-25 01:09PM	Can Centene's Q3 Earnings Escape Industry's Cost Headwinds? (Zacks)
Oct-23-25 12:42PM	Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings? (Zacks)
Oct-21-25 12:13PM	Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here (Zacks)
Sep-02-25 08:00AM	Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-25 04:01PM	Erasca Reports Second Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +5.41%
Jul-31-25 11:40PM	Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors (Insider Monkey) -8.71%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
Jun-02-25 08:00AM	Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 (GlobeNewswire)
May-29-25 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire) +31.82%
04:05PM	Loading…
May-13-25 04:05PM	Erasca Reports First Quarter 2025 Business Updates and Financial Results (GlobeNewswire)
08:00AM	Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway (GlobeNewswire)
May-07-25 08:00AM	Erasca to Present at the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-25 04:05PM	Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting (GlobeNewswire)
Apr-25-25 11:33AM	Erasca, Inc.: Carving A Different Niche In RAS Signaling (Seeking Alpha)
Apr-16-25 10:16AM	Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-25-25 04:31PM	Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-20-25 04:01PM	Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results (GlobeNewswire)
Jan-31-25 08:00AM	Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-21-25 09:35AM	Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-20-25 09:35AM	Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround (Zacks)
Jan-17-25 09:35AM	Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-16-25 09:35AM	Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-07-25 08:00AM	Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
09:55AM	Loading…
Nov-15-24 09:55AM	Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-12-24 04:01PM	Erasca Reports Third Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise (GlobeNewswire)
Sep-25-24 08:00AM	Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium (GlobeNewswire) +8.09%
Aug-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-24 10:53PM	ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 (InvestorPlace) +7.92%
04:01PM	Erasca Reports Second Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Jun-18-24 12:14PM	Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma (Clinical Trials Arena)
08:00AM	Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma (GlobeNewswire)
Jun-04-24 09:55AM	Should You Buy Erasca, Inc. (ERAS) After Golden Cross? (Zacks)
May-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 04:05PM	Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-17-24 07:14AM	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs (MT Newswires) +6.49%
05:51AM	Erasca restructures; Novartis moves to complete MorphoSys deal (BioPharma Dive)
05:31AM	Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options (FierceBiotech.com)
04:11AM	Erasca Prices $160 Million Common Stock Offering (MT Newswires)
May-16-24 08:02PM	Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise (GlobeNewswire)
08:00PM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
May-08-24 11:55PM	ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 (InvestorPlace) -8.84%
04:01PM	Erasca Reports First Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
May-07-24 08:00AM	Erasca to Present at the Bank of America Health Care Conference (GlobeNewswire)
Apr-24-24 04:05PM	Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31AM	Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ... (GuruFocus.com)
Mar-27-24 10:53PM	ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 (InvestorPlace)
08:30PM	Erasca Announces $45 Million Oversubscribed Private Placement Financing (GlobeNewswire)
04:01PM	Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results (GlobeNewswire)
Feb-14-24 08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
Feb-01-24 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 08:00AM	Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 01:34PM	3 Penny Stocks Youll Regret Not Buying Soon: December Edition (InvestorPlace) -5.08%
Dec-11-23 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma (GlobeNewswire)
Nov-28-23 08:00AM	Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) -11.38%
Nov-09-23 04:01PM	Erasca Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -8.64%
Nov-08-23 08:00AM	Erasca to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-12-23 11:28AM	Insiders Are Betting Millions on These 2 Stocks Heres Why You Might Want to Follow Their Lead (TipRanks)
Oct-10-23 03:56PM	Why Shares of Erasca Are Jumping Tuesday (Motley Fool) +13.18%
Sep-19-23 08:00AM	Erasca to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-29-23 08:00AM	Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors (GlobeNewswire)
Aug-10-23 04:01PM	Erasca Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire) +11.92%
Jul-12-23 06:35AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Jun-22-23 04:01PM	Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma (GlobeNewswire) -7.96%
Jun-15-23 06:22AM	Jonathan Lim Spends US$275k On Erasca Stock \ (Simply Wall St.)
Jun-06-23 10:53AM	Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals (Benzinga) -8.18%
Jun-05-23 04:01PM	Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline (GlobeNewswire) +14.19%
Jun-01-23 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 08:00AM	Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor (GlobeNewswire)
May-25-23 05:00PM	Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting (GlobeNewswire) -5.07%
09:01AM	With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest (Simply Wall St.)
May-16-23 08:00AM	Erasca Further Strengthens Business Leadership with Two Key Promotions (GlobeNewswire)
May-15-23 04:01PM	Erasca Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-02-23 08:00AM	Erasca to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 08:00AM	Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma (GlobeNewswire)
Apr-26-23 05:00PM	Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma (GlobeNewswire)
Apr-18-23 09:00AM	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 08:00AM	Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development (GlobeNewswire) -8.83%
Mar-31-23 06:19AM	Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few More Shares (Simply Wall St.)
Mar-30-23 04:21AM	6 analyst picks of the day: Walmart stock pops, Fluence upped to Buy \| Pro Recap (Investing.com)
Mar-23-23 04:01PM	Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:31PM	Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting (GlobeNewswire)
Feb-01-23 08:00AM	Erasca to Present at the Guggenheim Oncology Conference 2023 (GlobeNewswire)
Jan-16-23 06:19AM	We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-11-23 03:04PM	11 Best All-Time Low Stocks To Buy Now (Insider Monkey) +8.00%
Jan-04-23 08:00AM	Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 08:00AM	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors (GlobeNewswire)

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Erasca Foundation	Foundation	Dec 15 '25	Proposed Sale	3.65	8,333	30,439	Dec 15 08:11 PM
Erasca Foundation	Erasca Foundation	Nov 17 '25	Proposed Sale	2.60	8,333	21,626	Nov 17 04:27 PM
Erasca Foundation	Erasca Foundation	Oct 15 '25	Proposed Sale	2.47	8,333	20,591	Oct 15 03:43 PM
Erasca Foundation	Erasca Foundation	Sep 15 '25	Proposed Sale	1.55	8,333	12,942	Sep 15 04:21 PM
Erasca Foundation	Erasca Foundation	Aug 15 '25	Proposed Sale	1.54	8,333	12,835	Aug 15 03:21 PM
Erasca Foundation	Affiliate	Jul 15 '25	Proposed Sale	1.42	8,333	11,817	Jul 15 03:56 PM
Erasca Foundation	Affiliate	Jun 16 '25	Proposed Sale	1.42	8,333	11,813	Jun 16 03:16 PM
Erasca Foundation	Affiliate	May 15 '25	Proposed Sale	1.19	8,333	9,902	May 15 04:15 PM
Erasca Foundation	Affiliate	Apr 15 '25	Proposed Sale	1.22	8,333	10,165	Apr 15 03:56 PM
Erasca Foundation	Affiliate	Mar 17 '25	Proposed Sale	1.40	8,333	11,702	Mar 17 04:41 PM
Erasca Foundation	Affiliate	Feb 18 '25	Proposed Sale	1.53	8,333	12,752	Feb 18 03:57 PM
Erasca Foundation	Affiliate	Jan 15 '25	Proposed Sale	1.94	8,333	16,183	Jan 15 02:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS

Erasca Inc

Upgrade your FINVIZ experience